Viral Dynamics of Acute HIV-1 Infection by Little, Susan J. et al.
 
841
 
The Journal of Experimental Medicine • Volume 190, Number 6, September 20, 1999 841–850
http://www.jem.org
 
Viral Dynamics of Acute HIV-1 Infection
 
By Susan J. Little,
 
*
 
 Angela R. McLean,
 
‡
 
 Celsa A. Spina,
 
§
 
i
 
Douglas D. Richman,
 
*
 
§
 
i
 
 and Diane V. Havlir
 
*
 
From the 
 
*
 
Department of Medicine, University of California San Diego, San Diego, California 
92103; the 
 
‡
 
Institute for Animal Health, Compton, Newbury RG20 7NN, United Kingdom; 
the 
 
§
 
Department of Pathology, University of California San Diego, La Jolla, California 92093; 
and the 
 
i
 
Department of Veterans Affairs Medical Center, San Diego, California 92161
 
Summary
 
Viral dynamics were intensively investigated in eight patients with acute HIV infection to de-
fine the earliest rates of change in plasma HIV RNA before and after the start of antiretroviral
therapy. We report the first estimates of the basic reproductive number (
 
R
 
0
 
), the number of
cells infected by the progeny of an infected cell during its lifetime when target cells are not de-
pleted. The mean initial viral doubling time was 10 h, and the peak of viremia occurred 21 d
after reported HIV exposure. The spontaneous rate of decline (
 
a
 
) was highly variable among
individuals. The phase 1 viral decay rate (
 
d
 
I
 
 5 
 
0.3/day) in subjects initiating potent antiretrovi-
ral therapy during acute HIV infection was similar to estimates from treated subjects with
chronic HIV infection. The doubling time in two subjects who discontinued antiretroviral
therapy was almost five times slower than during acute infection. The mean basic reproductive
number (
 
R
 
0
 
) of 19.3 during the logarithmic growth phase of primary HIV infection suggested
that a vaccine or postexposure prophylaxis of at least 95% efficacy would be needed to extin-
guish productive viral infection in the absence of drug resistance or viral latency. These mea-
surements provide a basis for comparison of vaccine and other strategies and support the valid-
ity of the simian immunodeficiency virus macaque model of acute HIV infection.
Key words: basic reproductive number • viral decay • primary HIV • lymphocyte dynamics • 
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A
 
cute infection with HIV is characterized by an expo-
nential rise in viral titers to extraordinary levels in the
plasma (1, 2). In many individuals, this dynamic phase of
viral infection is accompanied by an acute syndrome re-
sembling infectious mononucleosis (3, 4). Viral titers spon-
taneously decline over a period of months to variable
steady state levels that predict HIV disease progression (5, 6).
The dynamics of viral replication in acute HIV infection
provide important insights into the initial events of HIV
pathogenesis. The basic reproductive number (the number
of infected cells that arise from a single HIV-infected cell
before any depletion of target cells) (7) can be estimated
from the initial rise in levels of HIV RNA in plasma (8).
An estimate of efficacy for an intervention, which prevents
sustained propagation of HIV infection from productively
infected cells, can be calculated from the basic reproductive
number. This estimate has particular relevance for vaccine
development, the only intervention likely to influence the
global HIV epidemic. It also has important implications for
postexposure prophylaxis routinely recommended after oc-
cupational exposure to HIV (9, 10) and certain empirically
defined sexual exposures (11).
The viral dynamics of primary infection have been char-
acterized for simian immunodeficiency virus (SIV)
 
1
 
 infec-
tion in the macaque (12) and demonstrated the first in vivo
estimates of 
 
R
 
0
 
 ranging from 2.2 to 68. It is critical, how-
ever, to establish estimates of viral production and clearance
in acute HIV infection in humans both for potential thera-
peutic applications and for validation of the SIV model. In
this report, viral dynamics before and after the initiation of
potent antiretroviral therapy were characterized in eight
subjects with acute HIV infection who were identified be-
fore development of an HIV antibody response or during
exponential viral decay.
 
Materials and Methods
 
Human Subjects.
 
Eight adults with a symptomatic viral illness
after sexual exposure to HIV were referred to our clinic for eval-
uation. Seven subjects had acute HIV infection, as defined by de-
 
1
 
Abbreviations used in this paper:
 
 PID, patient identification number; SIV,
simian immunodeficiency virus. 
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tectable HIV RNA in the plasma and nonreactive HIV antibody
test or indeterminate Western blot (see Table I). One subject pre-
sented with a positive HIV enzyme immunoassay and a positive
Western blot (two bands; p24 and gp120/160 were positive) in
the setting of exponential decline of plasma HIV RNA. All study
subjects signed an informed consent approved by the University
of California San Diego Human Subjects Committee. Baseline
(day 0) demographic information, risk assessment for HIV expo-
sure, clinical features, and duration of signs and symptoms com-
patible with an acute retroviral syndrome were recorded. The
date of HIV infection was ascertained from patient history by Dr.
S.J. Little. For individuals unable to identify a single high-risk ex-
posure, the range of potential exposure dates was recorded and
the midpoint in this range was assigned as the HIV exposure date.
This was an observational study, and participants chose to ini-
tiate antiretroviral therapy in conjunction with their physicians.
Subjects 001 and 002 subsequently interrupted their antiretroviral
therapy against advice 160 and 34 d, respectively, after treatment
initiation (see Fig. 1). Frequent whole blood samples were ob-
tained for isolation of plasma and PBMCs. Samples were col-
lected every 1–2 d for weeks 1 and 2, twice per week for week 3,
weekly for weeks 4–6, and every 4 wk thereafter. Whole blood
was collected in acid-citrate dextrose tubes and processed within
6 h of collection. Plasma was separated and stored at 
 
2
 
70
 
8
 
C.
PBMCs were separated by established density gradient methods
and prepared by controlled rate freezing for storage at 
 
2
 
150
 
8
 
C.
 
Virologic Studies.
 
HIV enzyme immunoassay (Abbott Labs.)
and Western blot (Cambridge Biotech Corp.) were performed at
presentation and repeated at regular intervals until a positive anti-
body and Western blot were documented. Plasma HIV RNA
measures were performed by the Roche Amplicor Assay (Roche
Molecular Systems) according to the manufacturer’s instructions.
The Roche ultrasensitive assay was used to determine HIV RNA
copy number on a subset of samples. A virologic “plateau” was
defined as at least two measures of HIV RNA, which varied by
less than threefold and occurred before the initiation of antiretroviral
therapy.
 
T Lymphocyte Studies.
 
Assessment of T cell subsets was per-
formed on whole blood within 24 h of specimen collection by
dual color FACS™ analysis (FACScan™; Becton Dickinson Cy-
tometry Systems). Baseline (day 0) T cell subsets were collected
within 7 d of the day 0 visit, except for subjects 001 and 002, for
which the first CD4 assessments were performed 11 and 37 d af-
ter presentation, respectively.
 
Modeling of Acute HIV Infection.
 
Fig. 2 schematically illustrates
the viral dynamics of acute HIV infection and is adapted from a
study of acute SIV dynamics (12). This figure demonstrates the
viral parameters measured in our study population. These param-
eters are based on a standard model of infected cell dynamics (
 
I
 
)
where free virus is used as a surrogate for infected cells:
 where 
 
T
 
 represents the target cell number,
 
d
 
I 
 
the death rate of infected cells, 
 
b
 
 the rate of new infection of
uninfected cells, and 
 
I
 
 the number of infected cells. We do not
explicitly include free virus; our model assumes that direct cell–
cell transmission is the most important mode of spread of
infection. If this were not true, we would use the same model,
but the definition of 
 
b
 
 would change to include a constant of
proportionality relating free virus density to infected cell density.
The inferred growth rate, 
 
r
 
0
 
, represents the initial rate of rise of
viremia per cell per day and is related to the model equation by
setting   so that   and 
The inferred growth rate, 
 
r
 
0
 
, was measured directly in one of our
study subjects (patient identification number [PID] 059). The ob-
dI dt ¤b IT dII, – =
r0 bT0 dI – = dI dt ¤ r0I = It () I0e
r0t. =
 
served rate of rise of viremia,  , is the measured slope of rising
viremia within days of the peak of viremia. Measurements of 
are obtained at a time when the slope of the observed rate of rise
 of HIV RNA is likely to be slower than that observed initially
(
 
r
 
0
 
). The inferred 
 
r
 
0
 
 assumes that (a) the CD4 cell count before
HIV infection (
 
T
 
0
 
) is 1,000 cells/mm
 
3
 
, (b) the efficiency of infec-
tion, 
 
b
 
, does not change between the time of infection and the
observed time, and (c) the life span of an infected cell remains
constant. The rationale underlying an inferred calculation for 
 
r
 
0
 
was that part of the slowdown in growth rate could be attributed
to depletion of target cells (13, 14). This assumption is supported
by the recent observation that in a comparison of SIV-infected
monkeys with and without CD8
 
1
 
 cells, viral dynamics up to and
including the time of peak viremia were not affected by the pres-
ence or absence of CTLs (15). Using total CD4 counts as the best
available surrogate for target cells and a nominal normal value of
1,000 cells/mm
 
3
 
, we corrected the observed rate of rise for the
degree of target cell depletion. Based on the observed growth
rate for the four study subjects identified with rising viremia  ,
the following formula was used to calculate an inferred initial
growth rate (
 
r
 
0
 
):
 
(1)
 
from the observed growth rate,  , where   represents the CD4
cell count at (or close to) the first viremia observation. If the in-
fected cell death rate had already grown larger by the time we
made our observations, this formula would underestimate 
 
r
 
0
 
 by
the amount of that change.
The initial viral doubling time, 
 
t
 
2
 
, is calculated using the slope
of rising viremia over time. The slope of declining viremia over
time is used to measure the rate of decline of viremia during the
subsequent spontaneous decline of viremia, 
 
a
 
, and the phase 1
(first order) viral decay rate after initiation of potent antiretroviral
therapy, 
 
d
 
I
 
. In the two subjects who discontinued antiretroviral
therapy against advice, the rate of rise of viremia,
 
 r
 
, after interrup-
tion of therapy was also measured.
The number of secondary infections arising from one infected
cell over the course of its life span, when target cells are not de-
pleted, is the basic reproductive number, 
 
R
 
0
 
. We estimated 
 
R
 
0
 
using a model that incorporates a fixed time delay, 
 
t
 
, between the
infection of a target cell and the subsequent production of prog-
eny virions. This fixed delay model gives 
 
R
 
0
 
 as:
The actual duration of the intercellular lag between infection
of a target cell and production of progeny virions is likely to be
between 12 and 24 h, as determined by in vitro and in vivo esti-
mates (16–18). We used a 24-h delay (eclipse period) from the
infection of one target cell and the subsequent production of
progeny virions for the fixed delay model.
A second model without delay was also investigated. Although
this is not a biologically plausible model, it was included for com-
parison with prior studies in macaques (12). The model without
delay is a special case of the fixed delay model with the delay set
to zero (
 
t 5 
 
0):
This model assumes the instantaneous production of progeny
virions from the moment of initial infection of a target cell and
almost certainly generates minimal estimates of 
 
R
 
0
 
.
These methods of inferring 
 
r
 
0
 
 and 
 
R
 
0
 
 from   and   allow us
to combine information on viral growth rate and degree of target
r ˆ
r ˆ
r ˆ ()
r ˆ ()
r0 T0 T ˆ ¤ () r ˆ dI + () d I – =
r ˆ T ˆ
R0 T0 T ˆ ¤ () 1 r ˆ dI ¤ + () e
r ˆt. =
R0 T0 T ¤ () 1 r ˆ dI ¤ + () . =
r ˆ T ˆ 
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cell depletion. They are sensitive to the allotted values of 
 
t
 
 and
T0. Thus, for patient 004, if T0 takes values of 500, 1,000 or
1,500, then R0 5 4.5, 9.1, or 13.6, respectively. If t was 12 rather
than 24 h, values of R0 would be intermediate between those
shown for the two different models.
Results
Acute Retroviral Illness. Eight subjects (seven men and
one woman) were referred to our clinic 2–35 d after the
onset of an acute retroviral illness and 12–50 d after high-
risk sexual exposure to HIV (Table I). Patient recall of HIV
exposure date placed the interval between HIV exposure
and the onset of symptoms between 8 and 47 d in this co-
hort (mean, 22 d). Seven of the eight subjects initiated po-
tent antiretroviral therapy 26–63 d after their reported HIV
exposure (Table I).
All subjects exhibited diffuse lymphadenopathy at pre-
sentation. Myalgias, fever, headache, and fatigue were re-
ported in 63–88% of subjects. CD4 cell numbers at initial
presentation were highly variable, ranging from 163 to 937
cells/mm3 (Table I). The CD4/CD8 T cell ratio was
within a normal range (2.0 6 0.8) in two of eight patients
who presented less than 2 wk after HIV exposure but was
low (0.2–1.0) in the remaining six subjects identified more
than 2 wk after HIV exposure (data not shown).
Viral Doubling Time during Rising Viremia. Four of the
eight subjects were identified before attaining peak levels of
acute viremia, which ranged from 2.5 to 22 million HIV
RNA copies per milliliter of plasma (Fig. 1). The mean
time from reported HIV exposure to the peak measure of
viremia was 21 d (range, 12–31 d; Table I). Sequential
measures of plasma viremia were obtained to estimate the
rates of rising HIV RNA (r0) before the initiation of anti-
retroviral therapy (Fig. 2). Subject 059 had a serum HIV
RNA of 30 copies/ml serendipitously obtained 3 d after
his reported HIV exposure. His plasma HIV RNA copy
number upon presentation with an acute retroviral illness 9 d
later (12 d after reported exposure) was 21,617,100 copies/ml.
The observed initial rate of rise of HIV RNA (r0) was 1.5/
day in this subject, which corresponds to a viral doubling
time (t2) of 12 h (Table II).
The observed rate of rise of viremia   for the other
three subjects ranged from 0.2 to 1.3/day (Table II). Be-
cause these plasma HIV RNA measurements were col-
lected within days of the peak and likely reflect a reduced
exponential growth rate   compared with the initial rate
(r0), we calculated an inferred initial rate (Fig. 2). These in-
ferred r0 values ranged from 1.4 to 3.5/day (mean, 2.0), and
the mean doubling time (t2) was 0.3 d, or 7 h. Comparison
of the observed initial rate of rise of viremia (r0) for subject
059 and the mean inferred rate, r0, for the remaining sub-
jects revealed similar estimates of r0 (1.5 and 2.0/day, re-
spectively) and a mean viral doubling time (t2) of 10 h.
The Basic Reproductive Number. The basic reproductive
number (R0) is the estimate of the number of secondary in-
fections arising from one infected cell over the course of its
life span when target cells are not a limiting resource. Using
r ˆ ()
r ˆ ()
Table I. Subject Characteristics
Subject
(PID)
Age/
sex
HIV
EIA/WB‡
Interval
between HIV
exposure and
presentation
Baseline
HIV RNA
Time from
exposure
to peak
Peak HIV
RNA CD4
Total
symptom
duration
Interval between
HIV exposure
and start of
ARV Rx
Antiretroviral
regimen
d copies/ml d copies/ml cells/mm3 dd
001 45/M Neg/ND 23 44,443,601 – – 937 14 35 ZDV/3TC/IDV
002 21/M Neg/ND 49 226,820 – – 163 35 58 ZDV/3TC/IDV
004 32/M Neg/ND 21 738,240 23 10,328,200 450 14 29 ZDV/3TC/IDV
044 28/M Neg/ND 16 19,200,000 – – 397 6 26 ZDV/3TC/NFV
045 28/F Pos/Ind. 26 1,767,250 31 6,235,500 314 9 53 ABC/APV
054 38/M Pos/Pos 50 438,501 – – 255 14 63 ZDV/3TC/NFV
056 29/M Neg/ND 12 534,600 16 2,491,300 354 3 57 IDV/EFV
059 39/M Neg/ND 12* 21,617,100 12 21,617,100 288 4 N/A –
Mean 33 26 2,445,601 21 7,674,142 395 12 46
Patient characteristics are shown. HIV exposure date was estimated for all study subjects. The intervals between HIV exposure and baseline (presen-
tation) HIV RNA, peak HIV RNA, and start of antiretroviral therapy are shown. CD4 and CD8 cell counts were collected at presentation for sub-
jects 004, 044, 045, 056, and 059. The first CD4 cell subsets were collected 11 and 37 d after presentation of subjects 001 and 002, respectively.
Mean values for plasma HIV RNA are geometric means; all other means are arithmetic. ABC, abacavir; APV, amprenavir; ARV Rx, antiretroviral
therapy; EFV, efavirenz; IDV, indinavir; Ind., indeterminate; N/A, not applicable; NFV, nelfinavir; 3TC, lamivudine; ZDV, zidovudine.
*Stored serum from 3 d after HIV exposure was identified retrospectively from this subject.
‡EIA, enzyme immunoassay; WB, Western blot; ND, not done.844 Viral Dynamics of Acute HIV-1 Infection
Figure 1. Plasma viral load was measured in the eight study subjects (A and B) from the estimated HIV exposure date through day 150 of follow-up.
(A) Patients identified during rising viremia. (B) Patients identified after the peak of plasma viremia. Patients are indicated by the following symbols:
P001, h; P002, s; P004, u; P044, n; P045, s; P054, e; P056, n; and P059, e. Open symbols indicate RNA measurements before treatment (or after
treatment interruption), and closed symbols indicate RNA measurements while on therapy. Arrows mark the start of antiretroviral therapy for the seven
treated subjects. Subject P059 did not receive antiretroviral therapy during the follow-up period and is identified by the e in A.845 Little et al.
a standard model, which assumes no delay between the in-
fection of a cell and the production of progeny virions, R0
values ranged from 5.2 to 9.1, with a mean value of 7.1
(95% confidence interval, 4.3–13.2; Table II). Slightly
greater values were obtained using a fixed delay model for
R0, which incorporates a 24-h delay between the infection
of a target cell and the subsequent production of progeny.
The fixed delay model, which is more biologically plausi-
ble, generated estimates of R0 ranging from 7.4 to 34.0,
with a mean value of 19.3 (95% confidence interval, 5.4–
54.3). These estimates suggest that z19 infected cells will
arise from each HIV-infected cell over the course of its life
span when CD4 target cells are not limiting. Furthermore,
these R0 estimates predict that an antiretroviral regimen or
vaccine, which is at least 95% effective, will prevent sus-
tained viral propagation in the absence of drug resistance or
viral latency. These are probably worst case estimates for
the required efficacy of a prophylactic vaccine, as they are
derived from viremic patients. This estimate of the value of
the basic reproductive number must be treated as an at-
tempt to gain an order of magnitude estimate rather than a
definitive value.
Table II. Initial Viral Replication Dynamics and Calculated R0 Values
Subject
(PID)
Observed
initial rise Observed rise Inferred initial rise
Calculated R0 value
r0/d t2(d) /d t2(d) r0/d t2(d)
Standard model
(no delay)
Fixed delay
(24 h)
059 1.5 0.5 – – – – 5.2 23.2
004 – – 1.3 0.5 3.5 0.2 9.1 34.0
045 – – 0.2 2.9 1.4 0.5 5.9 7.4
056 – – 0.4 1.6 1.6 0.4 8.1 12.4
Mean – – 0.5 1.3 2.0 0.3 7.1 19.3
The mean inferred r0 was 2.0 among the three subjects with an observed   value. The mean r0 for all four study subjects was 1.9 (three inferred rates
and one observed), which corresponds to a viral doubling time (t2) of 0.4 d. Viral dynamic parameters include: r0, the initial rate of rise of plasma
viremia per cell per day, shown either as an observed (directly measured) or inferred (calculated from  ) parameter; t2, the initial viral doubling time;
, the rate of rise of plasma viremia per cell per day within days of the peak of HIV RNA; and R0, the basic reproductive number. The mean R0 (no
delay) was 7.1, with a 95% confidence interval of 4.3–13.2. The mean R0 (24-h fixed delay) was 19.3, with a 95% confidence interval of 5.4–54.3.
95% confidence intervals for R0 were calculated by fitting a slope to all data points from 3 d before the peak to the peak of viremia and using the
variability in the estimate of this slope as the sole source of uncertainty in estimating R0. All means are geometric, except those for R0, which are
arithmetic.
r ˆ
r ˆ
r ˆ
r ˆ
Figure 2. A schematic illustration of the viral
dynamics of acute HIV-1 infection and the viral
parameters we measured is shown and adapted
from an article by Nowak et al. (12) in the Jour-
nal of Virology, 1997, vol. 71, pp. 7518–7525 by
copyright permission of the American Society
for Microbiology. An initial exponential rise of
viremia, r0, is observed followed by a spontane-
ous decline of viremia, a. The rate of rise of
HIV RNA,   which occurs within days of the
peak of viremia, is less than the rate, r0, ob-
served initially. Upon initiation of potent anti-
retroviral therapy, the phase 1 decay rate, dI, is
measured. The rate of rise of viremia after inter-
ruption of therapy, r, is measured in two of our
subjects.
r ˆ,846 Viral Dynamics of Acute HIV-1 Infection
Spontaneous Decline in Viral Titers. A spontaneous de-
cline of viremia was observed in all subjects before initia-
tion of antiretroviral therapy (Fig. 1). The measured rates
of decline of viremia (a), measured over the first 10 d of
spontaneous viral decay, were highly variable, with a range
of 0.1 to 0.8/day (mean, 0.3; Table III). The accompany-
ing t1/2 of spontaneous decline ranged from 0.9 to 12.3 d
(mean, 2.4). An apparent virologic plateau, defined as at
least two measures of HIV RNA that varied by less than
threefold, was observed a mean of 33 d after the peak mea-
sure of viremia in seven of the study subjects (data not
shown). In the absence of antiretroviral therapy, these early
plateau values for HIV RNA ranged from 7,074 to 436,354
copies/ml (mean, z165,000 copies/ml) and were sustained
for 2–4 wk in the absence of therapy. A subsequent further
spontaneous decline of HIV RNA was noted in subjects
056 and 059, who did not initiate therapy during the pla-
teau period.
Treatment Effects. Seven of eight subjects initiated po-
tent antiretroviral therapy during the first 2 mo after re-
ported HIV exposure. The initiation of potent antiretrovi-
ral therapy in these subjects permitted estimation of the
death rate of productively infected cells (dI) and the t1/2 of
virus during the decline of plasma viremia (Fig. 2). Values
for the phase 1 viral decay rate (dI) were remarkably consis-
tent and ranged from 0.2 to 0.5/day, with clearance t1/2 of
1.3–3.0 d for the subjects (Table III). Relapse of viremia
was observed after voluntary interruption of antiretroviral
therapy in two subjects (Table III). The mean rate of viral
replication upon relapse of viremia (r) was 0.4/day, corre-
sponding to a mean viral doubling time (t2) of 1.4 d. Com-
parison of the rate of viral replication after withdrawal of
treatment (r) to the rate of viral replication during initial
acute infection (r0) showed that the initial rate was nearly
five times faster (0.4 vs. 1.9/day).
Comparison of Viral Dynamics in HIV to the SIV Model.
A comparison of the viral replication dynamics during pri-
mary infection revealed remarkably similar parameters be-
tween the macaque model (12) with acute SIV infection
and human subjects with acute HIV infection (Table IV).
The mean initial rate of rise of viremia (r0) in 12
SIVsmE660-infected macaques was 2.2/day (range, 1.7–
2.7), with a viral doubling time of 0.32 d (8 h). This mea-
sure is similar to a mean r0 value of 1.9/day (range, 1.4–3.5)
and doubling time of 0.4 d (10 h) observed in our study
population. Both the magnitude and the time to peak of
viremia in the macaque and human infections were similar.
As observed in HIV-infected humans, a period of sponta-
neous decay of SIV after the peak of viremia is observed in
macaques with primary SIV infection. The mean rate of
spontaneous SIV decay (a) was 0.52/day, with a mean
clearance t1/2 of 1.33 d, compared with a mean rate of
spontaneous decay (a) of 0.3/day, with a mean viral clear-
ance t1/2 of 2.4 d in humans. Similar lower limit estimates
of R0 were observed in macaques (5.4) and humans (7.4)
using the fixed delay model (12), with more varied upper
limit estimates in the macaques, perhaps attributable to the
incorporation of data on target cell availability in the hu-
man study. Comparison of phase 1 decay rates and relapse
rates of viremia are limited by the very different treatment
regimens and durations of therapy used in the different
hosts as well as small sample numbers.
Discussion
Viral dynamics of acute HIV infection were described
nearly a decade ago (1, 2), yet only recently has the poten-
tial value of precisely defining viral and host immune re-
sponses in acute HIV infection been appreciated. The in-
creased recognition of the clinical syndrome associated
with primary HIV infection coupled with the potential
benefits of early intervention with potent antiretroviral
therapy have facilitated investigation of acute HIV infec-
tion (19, 20). Identifying patients with exponentially in-
creasing viral titers in this study permitted the first estimates
of viral doubling time associated with acute HIV infection.
The viral doubling time during acute HIV infection was
estimated to be 10 h. The abundance of permissive target
cells during acute HIV infection and the rapid viral dou-
bling time resulted in extraordinarily high levels of HIV
RNA (2.5–44 million copies per milliliter of plasma)
within 3 wk of infection. This estimate of the doubling
time in acute infection is nearly five times faster than that
measured after treatment interruption (t2 5 1.4 d) and what
Table III. Spontaneous Decline of Viremia and Viral Clearance 
after Initiation of Potent Antiretroviral Therapy
Subject
(PID)
Spontaneous
viral decay
Potent
ARV Rx
(down slope)
Off 
ARV Rx
(up slope)
a/d t1/2(d) dI/d t1/2(d) r/d t2(d)
001 0.8 0.9 0.3 2.3 0.5 1.3
002 0.1 12.3 0.5 1.3 0.4 1.5
004 0.4 1.6 0.4 1.6 – –
044 0.3 2.1 0.5 1.4 – –
045 0.4 1.9 0.3 2.5 – –
054 0.3 2.1 0.3 2.1 – –
056 0.5 1.5 0.2 3.0 – –
059 0.1 5.2 – – – –
Mean 0.3 2.4 0.3 1.9 0.4 1.4
Spontaneous decay (a) was measured from the slope of observed viral
decay between the peak of viremia and subsequent 10 d of follow-up.
t1/2, half life; t2, doubling time. Phase 1 viral decay rate in the setting of
potent therapy (dI) is measured from the slope of the observed viral de-
cay between the start date of therapy and subsequent 14 d of follow-up.
The rate of rise of viremia (r) after treatment interruption was measured
from the slope of observed relapse of viremia between the date of ther-
apy interruption and the next 7–14 d of follow-up. All means are geo-
metric means.847 Little et al.
has been observed after interruption of treatment of
chronic infection (t2 5 1.7 d; reference 21). The viral dou-
bling time after treatment interruption may represent an
objective parameter to evaluate the restoration of HIV-spe-
cific immune responses generated during therapy. A delay
before the emergence of detectable plasma HIV RNA after
therapy withdrawal or a slower viral doubling time than
was observed with our patients may provide a quantitative
estimate of acquired host immunity. We cannot, however,
exclude the possibility that greater target cell availability
during acute infection supports the observed more rapid vi-
ral doubling.
The quantitation of viral titers during acute infection also
permitted estimation of the basic reproductive number
(R0). Any intervention that reduces R0 to ,1 results in less
than one secondary infected cell arising from each HIV in-
fected cell. This parameter provides an estimate of how ef-
fective an intervention must be to result in extinction of vi-
ral replication and thus has significant implications for
vaccine design and postexposure therapies. To extinguish
ongoing viral replication, any intervention must reduce the
basic reproductive number to below one. At least two im-
portant qualifications must be considered before claiming
that such an intervention will successfully control HIV in-
fection. First, ongoing replication in the presence of the se-
lective pressure of an immune response or drug therapy
could permit the outgrowth of resistant (escape) mutants.
Consideration of resistance is relevant because both zi-
dovudine (22, 23) and multidrug-resistant virus (24) have
already been reported in acute HIV infection. Further-
more, mathematical models suggest that drug resistance is
more likely to develop if treatment is initiated during the
very high titer viremia of acute HIV infection (25). Sec-
ond, even during acute infection, latently infected CD4
cells are being generated (26), which upon later reactiva-
tion could provide the spark to rekindle viral replication.
Our estimates of R0 do not consider the impact of long-
lived pools of latently infected cells (27, 28), which have
been detected within the first week after the onset of an
acute retroviral syndrome (26).
Our estimates of the basic reproductive number ranged
from 7.4 to 34.0 (mean, 19.3) using the model with fixed
delay and suggest that after acute HIV infection, an inter-
vention at least 95% effective will be needed to prevent
sustained viral propagation. The presence of drug-resistant
virus or an established pool of latently infected cells could
make such a target extremely difficult to attain.
Our estimates of the basic reproductive number depend
on several additional assumptions. First, although biologi-
cally implausible, a no delay model was evaluated for the
purpose of comparison with prior studies of SIV dynamics
in acutely infected macaques. Second, our model assumes
that CD4 lymphocytes are a good surrogate for target cells.
This amounts to assuming that the fraction of CD4 cells
that are target cells is constant, an assumption that is born
out by our own preliminary observations (data not shown).
The lymphocyte populations, which are productively in-
fected in vivo, have not been precisely defined. Based upon
our observations that HIV replication in vitro is selectively
favored in CD4 cells of the memory phenotype (CD4/
CD45RO) (29), we and others speculated that activated
CD4 cells (30–33), such as memory cells expressing the IL-2
receptor (CD4/CD45RO/CD25) might represent a target
cell population for HIV infection in vivo. However, in the
absence of data defining the rate of production and clear-
ance of these cells (both infected and uninfected), we were
unable to fit a model that included these variables and used
absolute CD4 counts as the target cell population for our
estimates of R0. If the population of true target cells for
HIV infection was present as a stable proportion of the to-
tal CD4 cell population, then our estimates of R0 would be
unbiased. Supporting this assumption, we observed that the
Table IV. Acute HIV Infection Dynamics: HIV versus SIV
Parameter Human mean (range)
Macaque* mean
(range)
Early increase in viral load, r0 2.0 (1.4–3.5) 2.2 (1.7–2.7)
Doubling time (days), t2 0.3 (0.2–0.5) 0.32 (0.26–0.42)
Peak HIV RNA (copies/ml)‡ 7.7 3 106 (2.5–22) 2.0 3 106 (0.8–7.0)
Time to peak HIV RNA (days) 21 (12–31) 17 (10–21)
Spontaneous decline, a 0.3 (0.1–0.8) 0.52 (0.18–0.86)
Clearance half life (days), t1/2 2.4 (0.9–12.3) 1.33 (0.8–3.81)
Treatment decline, dI 0.3 (0.2–0.5) 0.74 (0.51–0.96)
Treatment cessation rebound, r 0.4 (0.4–0.5) 1.23 (0.45–1.77)
Reproductive number (standard), R0 7.1 (5.2–9.1) 3.6 (2.2–4.6)
Reproductive number (fixed delay), R0 19.3 (7.4–34.0) 36.5 (5.4–68)
*From reference 12.
‡Geometric mean.848 Viral Dynamics of Acute HIV-1 Infection
proportion of CD4 cells that coexpressed CD45RO/CD25
remained stable during the first 6 mo of follow-up in all
study subjects (data not shown). Third, we assumed a pre-
infection CD4 count of 1,000 cells/mm3. This would un-
derestimate R0 for subjects with preinfection T cell counts
(T0) . 1,000 and overestimate R0 for subjects with T0 ,
1,000.
Spontaneous decline of viremia was highly variable both
within and among patients. It is possible that the explana-
tion for this variability is attributable to host immune re-
sponses; however, there are yet no strong data to support
this assumption. Prior observations by Riggs et al. in a sin-
gle subject showed that the viral burst size appeared to be
stable during the decline of acute viremia, arguing against
the hypothesis that the life span of HIV-infected cells was
being shortened by effective CTL responses (34).
The rate of viral decay over the first 10 d of declining
viremia (a) was identical to the mean phase 1 viral decay
rate after initiation of potent antiretroviral therapy (0.3/d).
In one patient with peak HIV RNA counts over 10 mil-
lion, the rate of spontaneous decline was actually faster than
that seen after potent antiretroviral therapy (data not
shown). This observation is difficult to reconcile with the
assumption that during spontaneous decline, some new in-
fections are still being produced, whereas in the setting of
potent antiretroviral therapy, virtually all new infections are
blocked.
The initiation of potent antiretroviral therapy in the set-
ting of acute HIV infection resulted in measures of phase 1
viral decay rates remarkably similar to reported measures in
subjects with chronic HIV infection across a range of
treatment regimens (18, 21, 35, 36). In contrast to previous
reports (21, 37), no association between baseline HIV
RNA or CD4 cell count (or percentage) and the rate of
phase 1 viral decay was observed. These data suggest that
either an acquired host immune response develops very
early in the course of acute HIV infection and remains rel-
atively constant thereafter, or, conversely, that the contri-
bution of host immunity to the clearance of productively
infected cells is minimal in both acute and chronic HIV in-
fection (14, 34, 38).
Frequent measurements of plasma HIV RNA in these
subjects demonstrated the appearance of a relative virologic
plateau a mean of 33 d after the peak of viremia that has
not been identified in prior publications (14, 39). This vi-
rologic plateau occurred several months before the viro-
logic “set point” shown to be predictive of disease progres-
sion (5). Additional studies are needed to define the exact
timing, duration, and etiology of this observation.
Our measures of the initial rate of rise of viremia, magni-
tude of the peak, and subsequent spontaneous decline of
viremia are in close approximation to reported ranges for
these variables in a macaque model of primary SIV infec-
tion (12). Although the lower limit estimates for R0 are
similar for the human (7.4) and simian models (5.4), the
range for the basic reproductive number in the macaque
model was somewhat greater (5.4–68) than in the human
model (7.4–34.0). The more limited range of our estimate
is related to the use of both the viral growth rate and the
degree of target cell depletion to estimate R0, whereas the
SIV estimate of R0 used only viral dynamic parameters.
Similar viral replication dynamics between humans and
macaques support the use of the SIV model to study HIV
pathogenesis. Studies evaluating postexposure prophylaxis
as well as the establishment of viral latency will almost cer-
tainly be addressed more efficiently in the macaque model,
where route, inoculum, and viral strain are specified. Be-
cause candidate HIV vaccines will be evaluated first in the
SIV model, our estimates of the basic reproductive number
will provide a rational means to select vaccines that merit
testing in humans.
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